Accuracy, precision and linearity of the portable flow-volume meter Microspiro HI-298

The accuracy, precision and linearity of a new portable flow-volume meter, the Microspiro HI-298 (Chest Corporation, Tokyo, Japan), was investigated using a Fleisch no. 4 pneumotachograph as a standard. After connection and calibration of the pneumotachograph and the Microspiro, a healthy subject performed 44 forced vital capacity (FVC) manoeuvres at different levels of lung inflation. The FVC of these expirations ranged from 2.5-5.1 l. Linear regression of Microspiro values (dependent variable) on Fleisch pneumotachograph values (independent variable) showed that a good linear relationship existed: Pearson correlation coefficients ranged from 0.938-0.985. Linearity of the Microspiro was good except for the peak expiratory flow rate (PEFR) and the maximal expiratory flow at 25% of the expired volume (MEF75). The random error (measure of precision) of all flow-volume (F-V) indices was lower than 5%. The systematic error (measure of accuracy) was low for the forced expiratory volume in one second (FEV1) and the FVC (1% and 4.6%, respectively) but much higher for the instantaneous expiratory flows (PEFR 11.0%; MEF75 7.0%; MEF50 8.5%; MEF25 11.4%). Only the total error in FEV1 complied with the tolerance of 4% of the European Community for Coal and Steel (ECCS). When the measured values were adjusted according to the regression equations of this study, all F-V indices were accurate and precise within 5%. It was concluded that the portable Microspiro HI-298 is a useful instrument for bedside, work-site spirometry and for use in general practice.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				M. Albers, T. Schermer, G. van den Boom, R. Akkermans, C. van Schayck, C. van Herwaarden, and C. van Weel Efficacy of Inhaled Steroids in Undiagnosed Subjects at High Risk for COPD: Results of the Detection, Intervention, and Monitoring of COPD and Asthma Program Chest, December 1, 2004; 126(6): 1815 - 1824. [Abstract] [Full Text] [PDF]

				G. VAN DEN BOOM, M. P. M. H. RUTTEN-VAN MOLKEN, J. MOLEMA, P. R. S. TIRIMANNA, C. VAN WEEL, and C. P. VAN SCHAYCK The Cost Effectiveness of Early Treatment with Fluticasone Propionate 250 {micro}g Twice a Day in Subjects with Obstructive Airway Disease . Results of the DIMCA Program Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2057 - 2066. [Abstract] [Full Text] [PDF]

				S. G. M. Cloosterman, I. D. Bijl-Hofland, C. L. A. van Herwaarden, R. P. Akkermans, F. J. J. van den Elshout, H. T. M. Folgering, and C. P. van Schayck A Placebo-Controlled Clinical Trial of Regular Monotherapy With Short-Acting and Long-Acting {beta}2-Agonists in Allergic Asthmatic Patients Chest, May 1, 2001; 119(5): 1306 - 1315. [Abstract] [Full Text] [PDF]

				G. van den BOOM, C. P. van SCHAYCK, M. P. M. H. RUTTEN-van MOLKEN, P. R. S. TIRIMANNA, J. J. den OTTER, P. M. van GRUNSVEN, M. J. BUITENDIJK, C. L. A. van HERWAARDEN, and C. van WEEL Active Detection of Chronic Obstructive Pulmonary Disease and Asthma in the General Population . Results and Economic Consequences of the DIMCA Program Am. J. Respir. Crit. Care Med., December 1, 1998; 158(6): 1730 - 1738. [Abstract] [Full Text] [PDF]